Until now, there are no scientifically approved treatments for cannabis use disorder, which is an issue for those fighting drug dependence. The need is: Studies show that 47 percent of people who quit using marijuana experience withdrawal, while other research suggests 9 percent of people who use marijuana should be dependent on it. Will go
A solution, however, may be on the horizon. In a recent double-blind randomized controlled trial, researchers found that cannabidiol (CBD), a chemical compound found in cannabis, could actually help people quit.
The study team found that prescription-grade CBD modestly reduced cannabis intake and helped prevent people from using cannabis more than a placebo treatment. Prescription CBD is typically 16 times stronger than commercially available CBD.
“There are currently no safe and effective treatments available for prescriptions to help people suffering from cannabis,” study co-author Tom Freeman, a psychiatric researcher at the University of Bath, explains In the shlokas. “It is a large and unmet clinical need and can help people leave in an acceptable treatment format.”
If further studies confirm these findings, CBD could become an important tool for the estimated 22 million people who deal with this crisis-prone and life-changing issue.
The findings were published in the journal on Tuesday Lancet Psychiatry.
Experiment – To determine whether CBD is safe and can help people with cannabis use the disorder, researchers diagnosed the disorder with 82 people who were thought to be at least as serious as possible. .
This means that he experienced at least four of the 11 possible symptoms of addiction, including:
- Continuous substance use, regardless of whether there is a continuous or recurrent social or interpersonal problem or arising from the effects of the substance
- A lot of time is spent in the activities necessary to obtain the substance, use the substance, or recover from the effects.
“Most people who use cannabis do so without significant problems,” Freeman explains. “Others find that it has a substantial negative impact on their lives such as their ability to work, relationships with friends and family, and their mental and physical health.”
Study participants recognized that their cannabis use was interfering with optimal living and wanted to cut usage. Each participant expressed a desire to quit the following month, cut marijuana with tobacco, and had tried to consume cannabis at least once before.
Participants were randomly assigned to treatment groups and asked to take two capsules of prescription-grade CBD twice daily for four weeks. The placebo group was given sham capsules with no CBD, while others received daily doses of 200mg, 400mg or 800mg CBD.
All participants received six counseling sessions designed to help them use cannabis, which occurred before and during the study period.
During the study, researchers tested participants’ urine weekly for THC to find out how much hemp had been consumed in the previous week. Participants were also asked to report how many days before they had used cannabis that week.
Sham vs Treatment – At the beginning of the study, researchers described the 200-mg condition as ineffective.
However, from the findings of the study, both daily CBD doses of 400 and 800 mg were found. Reduce participants’ cannabis intake. Specifically, these doses decreased THC levels to −94.21ng / mL and −72.02ng / mL, respectively.
Those taking 400 to 800 mg of CBD were more likely to live longer than the placebo group: the 400 mg CBD group withheld for half a day per week. The 800 milligram dose group had 0.3 days of extra abstinence per week. Both CBD doses served better consumption and restraint than did placebo.
During the study, participants did not experience any serious adverse events related to the intake of CBD. The prescription of CBD is relatively safe for use, suggesting high quality.
The Future of CBD Research – It is unclear in studies why CBD helps people quit using marijuana. Previous research suggests that CBD can reduce cannabis craving and alleviate mental health symptoms such as anxiety, which in turn affects usage.
“Unlike CBD and often THC has opposite effects on our endogenous cannabinoid system,” Freeman says. “In this way, CBD is very different from a nicotine patch or other replacement therapy.”
THC, an active ingredient in marijuana that makes you “high”, binds specific brain receptors and affects reaction time, memory, and movement. CBD prevents brain receptors from binding to cannabinoids, and can make people feel more relaxed. In theory, this process may also explain why CBD can be helpful – but more research is needed to ascertain this.
Freeman and his colleagues did not persuade people to buy CBD for “self-medication” if they were trying to cut down on cannabis use.
CBD products sold without a prescription contain low doses of CBD – about 25 mg – and lack quality assurance, Freeman explains. Commercially available CBD products also contain a variety of supplements and sometimes contain THC. If you are looking for help, Freeman recommends you talk to a health care professional first.
The background: A substantial and precious clinical need exists for pharmacological treatment of cannabis use disorders. Cannabidiol may omit a novel treatment, but it is unclear whether the dose may be effective or safe. Therefore, we aimed to identify effective doses and eliminate unskilled doses in a Phase 2A trial using an adaptive Bayesian design.
Methods: We performed a Phase 2A, double-blind, placebo-controlled, randomized, adaptive Bayesian trial at the Clinical Psychopharmacology Unit (University College London, London, UK). We used an adaptive Bayesian dose-finding design to identify efficacious or inefficient doses in a priori-primary interim and final analysis steps. The first phase of the trial for 4 weeks of treatment with three different doses (200 mg, 400 mg, or 800) of oral cannabis randomly given to participants meeting the disorder criteria using cannabis from DSM-5 In (1: 1: 1: 1) was assigned. Milligrams) or by using double-blind block randomization sequences with matched placebo during the termination attempt. All participants received a brief psychological intervention of the motivational interview. For the second phase of the trial, new participants were randomly assigned to placebo or dosages in the interim analysis. The primary objective was to identify the most effective dose of cannabidiol to reduce cannabis use. The primary endpoints were low diuretics 11-nor-9-carboxy-à-9-tetrahydrocannabinol (THC-COOH): creatinine ratio, increase per week with avoiding cannabis during treatment, or both, as is evident from the posterior probabilities Cannabidiol is better. Placebo is greater than 0 · 9. All analyzes were performed on an intention-to-treat basis. The trial is registered with ClinicalTrials.gov (NCT02044809) and the EU Clinical Trials Register (2013–000361–36).
Test – Results: Between 28 May 2014, and August 12, 2015 (first phase), 48 participants randomized to placebo (n = 12) and cannabidiol 200 mg (n = 12), 400 mg (n = 12) and 800 mg. was assigned. (n = 12). In the interim analysis, cannabidiol 200 mg was removed from the test as an inefficient dose. Between May 24, 2016 and January 12, 2017 (second phase), randomization continued and an additional 34 participants were allocated 400 mg (n = 12) to cannabidiol 800 mg (n = 11) (1: 1). : 1). , And placebo (n = 11). In the final analysis, cannabidiol exceeded the primary endpoint criterion (0 · 9) for both 400 mg and 800 mg primary outcomes. For urinary THC-COOH: creatinine ratio, the most effective dose compared to placebo with observed data was likely 0 · 9995 for cannabidiol 400 mg and 0 · 9965 for cannabidiol 800 mg. For days with abstinence from cannabis, the most likely E “giant dose compared to placebo with observed data was 0 · 9966 for cannabidiol 400 mg and 0 · 9247 for cannabisboyl 800 mg. Comparison with placebo In, cannabidiol 400 mg decreased THC. -COOH: creatinine ratio -94 · 21 ng / ml (95% interval estimate -161 · 83 to -35 · 56) and 0 per week (48 · 15 days to 0 · 82) Increased abstinence from cannabis. Compared with placebo, THC-COOH decreased in cannabidiol 800 mg: creatinine ratio –72 · 02 ng / ml (–135 · 47 to –19 · 52) and up to 27 days per week An increase in abstinence from cannabis (–0 · 09) 0 · 64). Cannabidiol was well tolerated, with no serious adverse events reported, and 77 (94%) of the 82 participants completed treatment. did.
Explanation: In the first randomized clinical trial of cannabis for cannabis use disorder, cannabis 400 mg and 800 mg were safer and more effective than placebo in reducing cannabis use.